228. Lai CL, Gane E, Chao-Wei H, Thongsawat S, Wang Y, Chen Y, et al.
Two-Year results from the Globe Trial in patients with hepatitis B:
Greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine
[Abstract]. HEPATOLOGY 2006;44(Suppl):222A.
229. Di Bisceglie AM, Lai CL, Gane E, Chen Y-C, Thongsawat S, Wang Y, et
al. Telbivudine Globe Trial: Maximal early HBV suppression is predictive
of optimal two-year efficacy in nucleoside-treated hepatitis B patients.
HEPATOLOGY 2006;44(Suppl):230A-231A.
230. Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A
double-blind placebo-controlled study of emtricitabine in chronic hepatitis
B. Arch Intern Med 2006;166:49-56.
231. Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels
L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B
in human immunodeficiency virus/hepatitis B virus-coinfected individuals
for whom interferon-alpha and lamivudine therapy have failed. J Infect
Dis 2002;186:1844-1847.
232. Peters MG, Anderson J, Lynch P, Tun L, Alston-Smith B, Carol L, et al.
Randomized controlled study of tenofovir and adefovir in chronic hepatitis
B virus and HIV infection: ACTG A5127. HEPATOLOGY 2006;44:
1110-1116.
233. Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C,
et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in
HIV-infected patients. HEPATOLOGY 2006;43:548-555.
234. Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et
al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapynaive
and -experienced patients coinfected with HIV-1 and hepatitis B
virus. J Infect Dis 2004;189:1185-1192.
235. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the
treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol
2004;2:266-272.
236. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D,
et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-
resistant hepatitis B virus infection. HEPATOLOGY 2004;40:1421-
1425.
237. van Bommel F, Berg T. Reactivation of viral replication after replacement
of tenofovir by adefovir. HEPATOLOGY 2005;42:239-240.
238. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard
PM, et al. Fanconi syndrome and renal failure induced by tenofovir: a first
case report. Am J Kidney Dis 2002;40:1331-1333.
239. Yoo BC, Kim H, Lee KS, Kim TH, Paik SW, Ryu SH, et al. A 24-week
clevudine monotherapy produced profound on-treatment viral suppres-
538 LOK AND MCMAHON HEPATOLOGY, February 2007 sion as as sustained viral suppression and normalization of aminotransferase
levels for 24 weeks off-treatment in HBEAg( ) chronic hepatitis B
patients [Abstract]. HEPATOLOGY 2005;42(Suppl):270A.
240. Yoo BC, Koh KC, Chung YH, Han BH, Byun KS, UM S, et al. Clevudine
is highly efficacious in HBEAg( ) chronic Hepatits B patients with
a sustained antiviral effect after cessation of therapy [Abstract].HEPATOLOGY
2005;42(Suppl):268A.
241. Andreone P, Cursaro C, Gramenzi A, Zavagliz C, Rezakovic I, Altomare
E, et al. A randomized controlled trial of thymosin-alpha1 versus interferon
alfa treatment in patients with hepatitis B e antigen antibody–and
hepatitis B virus DNA–positive chronic hepatitis B. HEPATOLOGY 1996;
24:774-777.
242. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin
alpha1 in patients with chronic hepatitis B: a randomized, controlled
trial. HEPATOLOGY 1998;27:1383-1387.
243. Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman
HD, Peleman RR, et al. Thymosin alpha1 treatment of chronic hepatitis
B: results of a phase III multicentre, randomized, double-blind and placebo-
controlled study. J Viral Hepat 1999;6:397-403.
244. Zavaglia C, Severini R, Tinelli C, Franzone JS, Airoldi A, Tempini S, et
al. A randomized, controlled study of thymosin-alpha1 therapy in patients
with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis
Sci 2000;45:690-696.
245. Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the
treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment
Pharmacol Ther 2001;15:1899-1905.
246. Sung JJY LJ, Zeuzem S, Chow WC, Heathcote E, Perrillo R, Brosgart C,
et al. A randomized double-blind phase II study of lamivudine compared
to lamivudine plus adefovir dipivoxil for treatment nai¨ve patients with
chronic hepatitis B: week 52 analysis. J Hepatol 2003:25.
247. A Phase II Study of Lamivudine Compared to Lamivudine Plus Adefovir
Dipivoxil for Subjects With Chronic Hepatitis B. http://ctr.gsk.co.uk/
Summary/lamivudine/II_NUC20912.
248. Peters MG, Hann H, Martin P, Heathcote EJ, Buggisch P, Rubin R,
Bourliere M, et al. Adefovir dipivoxil alone or in combination with lamivudine
in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology
2004;126:91-101.
249. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, et al.
Combination therapy with interferon-alpha and ribavirin in patients with
dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol
2005;20:727-732.
250. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and
interferon is effective for hepatitis C virus clearance in hepatis B and C
dually infected patients. HEPATOLOGY 2003;37:568-576.
251. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, et al. High
doses of alpha-interferon are required in chronic hepatitis due to coinfection
with hepatitis B virus and hepatitis C virus: long term results of a prospective
randomized trial. Am J Gastroenterol 2001;96:2973-2977.
252. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al.
Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med
1994;330:88-94.
253. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al.
Long-term benefit of interferon alpha therapy of chronic hepatitis D:
regression of advanced hepatic fibrosis. Gastroenterology 2004;126:
1740-1749.
254. Niro G, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al.
Pegylated interferon alpha-2b as monotherapy or in combination with
ribavirin in chronic hepatitis delta. HEPATOLOGY 2006;44:713-720.
255. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M,
Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis
delta: relevance of quantitative RT-PCR for follow-up. HEPATOLOGY
2006;44:728-735.
256. Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC, et al.
Lamivudine for chronic delta hepatitis. HEPATOLOGY 1999;30:546-549.
257. Di Martino V, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, et
al. Influence of HIV infection on the response to interferon therapy and
the long-term outcome of chronic hepatitis B. Gastroenterology 2002;
123:1812-1822.
258. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B
virus (HBV) infection in coinfected patients receiving lamivudine as a
componet of anti-human immunodeficiency virus regimens. Clin Infect
Dis 2001;32:963-969.
259. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire
F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine
in human immunodeficiency virus-infected patitents. HEPATOLOGY
2000;31:1030-1031.
260. Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six-week efficacy of
combination therapy with lamivudine and tenofovir in patients coinfected
with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 2004;
39:1062-1064.
261. Sheldon JA, Corral A, Rodes B, Mauss S, Rockstroh J, Berger F, et al. Risk
of selecting K65R in antiretroviral-naive HIV-infected individuals with
chronic hepatitis B treated with adefovir. AIDS 2005;19:2036-2038.
262. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation
of hepatitis B virus replication in patients receiving cytotoxic therapy.
Report of a prospective study. Gastroenterology 1991;100:182-188.
263. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al.
Frequency of hepatitis B virus reactivation in cancer patients undergoing
cytotoxic chemotherapy: a prospective study of 626 patients with identi-
fication of risk factors. Journal of Medical Virology 2000;62:299-307.
264. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis
B virus reactivation during anticancer therapy. HEPATOLOGY 2006;43:
209-220.
265. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, et al.
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation
in HBV-carriers with lymphoma. HEPATOLOGY 2003;37:
1320-1328.
266. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation
in a chronic hepatitis B surface antigen carrier with rheumatoid
arthritis treated with infliximab and low dose methotrexate. Ann Rheum
Dis 2003;62:686-687.
267. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM.
Chronic hepatitis B reactivation following infliximab therapy in Crohn’s
disease patients: need for primary prophylaxis. Gut 2004;53:1363-1365.
268. Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, et al. Preemptive
use of lamivudine reduces hepatitis B exacerbation after allogeneic
hematopoietic cell transplantation. HEPATOLOGY 2002;36:702-709.
269. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is
superior to deferred preemptive lamivudine therapy for hepatitis B patients
undergoing chemotherapy. Gastroenterology 2003;125:1742-
1749.
270. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine
of hepatitis B virus reactivation in chronic HbsAg carriers with
lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;
115:58-62.
271. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive
lamivudine therapy based on HBV DNA level in HBsAg-positive kidney
allograft recipients. HEPATOLOGY 2002;36:1246-1252.
272. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al.
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in
patients with haematological malignancy on completion of cytotoxic chemotherapy.
Gut 2005;54:1597-1603.
273. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients
with acute hepatitis B (a series of cases). J Viral Hepat 2004;11:427-431.
274. Tillmann HL, Haden J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et
al. Safety and efficacy of lamivudine in patients with severe acute or
fulminant hepatits B: A multicenter experience. J Viral Hepatol 2006;4:
256-263.
275. Tassopoulos NC, Koutelou MG, Polychronaki H, Paraloglou-Ioannides
M, Hadziyannis SJ. Recombinant interferon-alpha therapy for acute hepatitis
B: a randomized double-blind, placebo-controlled trial. J Viral
Hepat 1997;4:387-394.
HEPATOLOGY, Vol. 45, No. 2, 2007 LOK AND MCMAHON 539 |
楼主: IC
发表于 2007-2-7 19:52
